Janssen's single-agent DARZALEX(R) (daratumumab) approved by EC for Treatment of MM
Janssen announced the EC has granted conditional approval to DARZALEX® (daratumumab) for monotherapy of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. May 23, 2016